All In Biotech

Drug Trial Radar · NCT07400107

AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

Efficacy and Safety of NNC0487-0111 s.c. Once-weekly Compared to Semaglutide s.c. Once-weekly in Participants With Overweight or Obesity, and Type 2 Diabetes (AMAZE 8)

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 985 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

985

Actual

Start

May 20, 2026

Primary completion

Dec 19, 2028

Study completion Dec 19, 2028

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Feb 10, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight and type 2 diabetes. Participant will receive 2 injections every week: an active medicine and a placebo, both taken as injections under the skin once a week. The placebo is a treatment with no active medicine in it and will be given to all participants. In addition to placebo, participants will receive either of the active medicine NNC0487-0111 (the treatment being tested) or Semaglutide (an approved and commonly prescribed treatment used as comparator). Which treatment participants get is decided by chance.

Conditions

  • Obesity
  • Overweight
  • Diabetes Mellitus, Type 2

Interventions

  • NNC0487-0111Drug

    NNC0487-0111 will be administered subcutaneously using PDS290 pre-filled pen-injectors to one of the body parts: thigh, abdomen or upper arm.

  • SemaglutideDrug

    Semaglutide will be administered subcutaneously using PDS290 pre-filled pen-injectors to one of the body parts: thigh, abdomen or upper arm.

  • Placebo (matched to NNC0487-0111)Drug

    Placebo matched to NNC0487-0111 will be administered subcutaneously using pre- filled pen-injectors to one of the body parts: thigh, abdomen or upper arm.

  • Placebo (matched to semaglutide)Drug

    Placebo matched to semaglutide will be administered subcutaneously using pre-filled pen-injectors to one of the body parts: thigh, abdomen or upper arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Relative change in body weightTime frame: From baseline (week 0) to week 84

Locations

122 sites in 14 countries. Site status is shown where the registry gives one.

  • Encore Medical Research LLC

    Hollywood, Florida

  • Optimal Research Sites

    Orange City, Florida

  • Encore Medical Research of Weston

    Weston, Florida

  • Endocrine Research Solutions, Inc

    Roswell, Georgia

  • Elite Clinical Trials

    Blackfoot, Idaho

  • Endo And Metab Cons

    Rockville, Maryland

  • Arcturus Healthcare, PLC.

    Troy, Michigan

  • Velocity Clin Res, Dallas

    Dallas, Texas

  • Consano Clinical Research, LLC

    Shavano Park, Texas

  • Selma Medical Associates

    Winchester, Virginia

  • Centro Médico Privado San Vicente Diabetes

    Córdoba, Argentina

  • Centro de Investigaciones Metabólicas

    Capital Federal, Buenos Aires, Argentina

  • Centro Médico CIMEL

    Lanús Este, Buenos Aires, Argentina

  • Núcleo de Pesquisa Clínica do Rio Grande do Sul Ltda.

    Porto Alegre, Rio Grande do Sul, Brazil

  • i9 Pesquisas Clínicas

    Campinas, São Paulo, Brazil

  • CPQuali Pesquisa Clínica Ltda

    São Paulo, São Paulo, Brazil

  • BR Trials - Ensaios Clínicos e Consultoria Ltda.

    São Paulo, São Paulo, Brazil

  • Dr. Tatyana Metalova - AIPSMCE EOOD

    Gotse Delchev, Bulgaria

  • Medical centre Zdrave 1 OOD

    Kozloduy, Bulgaria

  • UMHAT Pulmed OOD - Pazardzhik, Department of Internal Diseases

    Pazardzhik, Bulgaria

  • MHAT Heart and Brain EAD - Pleven, Endocrinology and Metabolic Diseases

    Pleven, Bulgaria

  • DCC I- Pleven EOOD Endocrinology

    Pleven, Bulgaria

  • MHAT Knyaginya Klementina - Sofia EAD

    Sofia, Bulgaria

  • MHAT Sveta Sofia EOOD, Department of Endocrinology and Metabolic diseases

    Sofia, Bulgaria

  • Acibadem City Clinic UMHAT Tokuda EAD, Endocrinology

    Sofia, Bulgaria

  • USHATE Akad. Ivan Penchev EAD, Second Clinic of Endocrinology

    Sofia, Bulgaria

  • Medical Institute of Ministry of interior

    Sofia, Bulgaria

  • Medical Centre - Clinic Nova EOOD

    Varna, Bulgaria

  • Poliklinika Medikol Zagreb

    Grad Zagreb, Croatia

  • Opca bolnica Karlovac

    Karlovac, Croatia

  • Specijalna Bolnica za medicinsku rehabilitaciju Krapinske Toplice_Endocrinology

    Krapinske Toplice, Croatia

  • Poliklinika SLAVONIJA OSIJEK

    Osijek, Croatia

  • Clinical Hospital Centre Rijeka_Endocrinology

    Rijeka, Croatia

  • General Hospital Dr. Josip Bencevic_Diabetic department

    Slavonski Brod, Croatia

  • Opca bolnica Varazdin_Endocrinology

    Varaždin, Croatia

  • Poliklinika Solmed

    Zagreb, Croatia

  • Herz- und Diabeteszentrum NRW - Bad Oeynhausen

    Bad Oeynhausen, Germany

  • Zentrum für klinische Studien Südbrandenburg GmbH

    Elsterwerda, Germany

  • Praxis am Markt Dr. Becker

    Essen, Germany

  • MVZ im Altstadt-Carree Fulda GmbH - Zentrum für klinische Studien

    Fulda, Germany

Showing 40 of 122 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.